Quercetin Dihydrate.

When quercetin neutralizes a free radical it becomes an oxidized quercetin radical, and ascorbate donates an electron to regenerate the intact molecule. This recycling lets the two support the body's antioxidant defenses longer than either does alone.

Quercetin's catechol structure binds the non heme iron in food and supplements, forming a complex the body absorbs poorly. Taking the two at the same meal lowers how much of that iron gets taken up, so spacing them apart supports normal iron status.

Both polyphenols are cleared by the same sulfation and glucuronidation enzymes, so quercetin can compete for those pathways and slow how quickly resveratrol is broken down. Their overlapping antioxidant chemistry also makes them a frequent pairing in formulas.

Green tea catechins are rapidly methylated by the enzyme COMT and pumped back out by intestinal efflux transporters, and quercetin competes at both steps. By occupying those routes it can leave more catechin available to be absorbed.

Both compounds act on NF-kB and NRF2 signalling that governs normal inflammatory and antioxidant enzyme output, and each blocks intestinal P-glycoprotein, so co-dosing raises the exposure of the other.

Quercetin and luteolin damp mast cell mediator release through the same calcium and kinase steps, so their effect on normal histamine handling runs through one shared mechanism.

The flavonol can donate an electron that returns oxidised tocopherol to its active form inside cell membranes, placing it in the same redox relay that regenerates vitamin E.

Oxidised quercetin forms a reactive quinone that glutathione conjugates and carries out of the cell, the normal clearance route for the spent flavonol.

The catechol group binds copper ions with high affinity, lowering the free copper available for intestinal uptake and altering the flavonol's own redox behaviour. Dosing the two apart avoids it.

Piperine slows intestinal glucuronidation and inhibits P-glycoprotein, the two limits on quercetin reaching circulation, so it is added specifically to raise that fraction.

Quercetin dihydrate is poorly water soluble, so it is routinely complexed with lecithin phospholipids into a phytosome that disperses in bile and crosses the intestinal membrane more readily.

Citrulline raises plasma arginine and feeds nitric oxide synthase, while quercetin has been studied for its effect on nitric oxide metabolite handling and oxidative markers. Kurtz and colleagues tested the pair in trained cyclists in two separate reports, one on nitric oxide metabolites and antioxidant biomarkers and one on time trial performance. The biomarker work is marker data rather than an outcome, and the performance report should be read on its own stated conclusion.

Rutin is quercetin-3-O-rutinoside, the same aglycone carrying a disaccharide. It must be deglycosylated by gut microbial glycosidases before the quercetin core is absorbed, which shifts uptake later and further down the gut than the free aglycone. The two are not interchangeable on a milligram basis and a formula carrying both delivers the aglycone on two different timelines.

Bromelain is a cysteine protease mixture from pineapple stem and is routinely combined with quercetin in flavonoid formulas, with the stated rationale that proteolytic activity aids uptake of the poorly soluble flavonol. Direct human bioavailability data for that specific claim is thin. The pairing is long-established formulation practice and is presented at that confidence rather than higher.

Quercetin's catechol and 3-hydroxy-4-keto sites bind divalent metal ions, and cell studies show it can move zinc across lipid membranes as a complex. That work is in vitro and describes ion movement, not a clinical outcome. The pairing is worth stating as chemistry a formulator should know about, at that level and no further.

Oxidised quercetin forms an electrophilic ortho-quinone that reacts with thiols, and N-acetylcysteine supplies exactly such a thiol along with cysteine for glutathione synthesis. The adduct chemistry is well described in vitro. Whether it changes anything measurable in people taking both has not been established, so the row stays at mechanism level.

Quercetin glycosides that escape small intestinal hydrolysis are deglycosylated and ring-fissioned by colonic bacteria into phenolic acids, and the composition of that community changes which metabolites appear. This is why absorption of glycoside-rich material varies between people. The relationship is established microbiology rather than a tested probiotic pairing.

Quercetin aglycone is poorly water soluble, and dispersing it in a medium-chain triglyceride vehicle is one of the standard formulation answers to that. Lipid vehicles raise the amount presented in a dissolved state at the absorptive surface. The effect on plasma levels depends on the specific formulation, so it is a formulation strategy rather than a fixed multiplier.

Apigenin and quercetin are both conjugated by the same intestinal and hepatic sulfotransferases and UDP-glucuronosyltransferases. Taken together at meaningful doses they contend for that shared conjugation capacity, which alters the free fraction of each. This is enzyme-level competition described in metabolism studies, and it can raise as well as lower exposure.

Pterostilbene is methylated and conjugated by the same phase II routes quercetin saturates at higher intakes. Co-dosing two polyphenols that load those enzymes changes the metabolite mix of both. Read it as a pharmacokinetic interaction between polyphenols rather than a benefit.

Sulforaphane modifies KEAP1 cysteines and releases Nrf2 to induce phase II enzymes; quercetin's oxidised quinone form is also electrophilic and engages the same sensor. Both therefore act on the antioxidant response element genes, by chemistry rather than by receptor binding. Stated as converging mechanism, not as a measured combined effect.

Dihydrolipoic acid reduces oxidised forms of other antioxidants, and the quercetin semiquinone and quinone are reducible species. Regenerating the parent flavonol extends its radical-scavenging life in a laboratory system. The interaction is chemistry established in vitro rather than an effect measured in people.

Grape seed proanthocyanidins and quercetin are both polyphenols with catechol groups and overlapping metal-binding and radical-quenching behaviour. Formulas combine them to widen the range of structures present rather than to raise the dose of any one. The rationale is compositional and the human data on the specific combination is limited.

Silymarin flavonolignans and quercetin are both extensively glucuronidated and both inhibit UGT isoforms in vitro. Combining them loads the same conjugation machinery, which can raise circulating unconjugated fractions of either. This matters most when other glucuronidated compounds are taken alongside.

Quercetin and caffeine appear together in endurance formulas, both having been studied around exercise performance by unrelated mechanisms. Quercetin is a weak adenosine receptor ligand in vitro, which has been raised as a point of overlap. The evidence for a specific combined benefit is thin and the row is labelled early for that reason.

Flavonols with a 3-hydroxy-4-keto arrangement form complexes with divalent cations including magnesium, which changes their solubility and colour in solution. In a co-formulated powder this affects appearance and dissolution more than absorption. It is a formulation chemistry note, not a nutritional interaction claim.